Suchergebnisse - "Jackson, Michael L"

PubPharm (273)

21

Vaccine Effectiveness against COVID-19 among Symptomatic Persons Aged ≥12 Years with Reported Contact with COVID-19 Cases, February – September 2021

enthalten in: bioRxiv.org | 2022

von Chung, J. | Kim, S. | Belongia, E. | +15

22

Role of Age in the Spread of Influenza, 2011-2019 : Data From the US Influenza Vaccine Effectiveness Network

enthalten in: American journal of epidemiology | 2022

von Griggs, E. | Flannery, B. | Foppa, I. | +13

23

Interactions among 17 respiratory pathogens: a cross-sectional study using clinical and community surveillance data

enthalten in: bioRxiv.org | 2022

von Burstein, R. | Althouse, B. | Adler, A. | +32

24

Interactions among 17 respiratory pathogens : a cross-sectional study using clinical and community surveillance data

enthalten in: medRxiv : the preprint server for health sciences | 2022

von Burstein, R. | Althouse, B. | Adler, A. | +32

25

Monitoring vaccine safety using the vaccine safety Datalink : Assessing capacity to integrate data from Immunization Information systems

enthalten in: Vaccine | 2022

von Groom, H. | Crane, B. | Naleway, A. | +18

26

Trends in COVID-19 vaccination intent and factors associated with deliberation and reluctance among adult homeless shelter residents and staff, 1 November 2020 to 28 February 2021 - King County, Washington

enthalten in: Vaccine | 2022

von Rogers, J. | Cox, S. | Hughes, J. | +13

27

Association of the COVID-19 Pandemic With Routine Childhood Vaccination Rates and Proportion Up to Date With Vaccinations Across 8 US Health Systems in the Vaccine Safety Datalink

enthalten in: JAMA pediatrics | 2022

von DeSilva, M. | Haapala, J. | Vazquez-Benitez, G. | +13

CommentIn: JAMA Pediatr. 2022 Jan 1;176(1):21-23. - PMID 34617971

28

Vaccine effectiveness against COVID‐19 among symptomatic persons aged ≥12 years with reported contact with COVID‐19 cases, February–September 2021

enthalten in: Influenza and Other Respiratory Viruses | 2022

von Chung, J. | Kim, S. | Belongia, E. | +15

29

Seroprevalence of SARS-CoV-2 Antibodies in Seattle, Washington: October 2019-April 2020

enthalten in: bioRxiv.org | 2021

von McCulloch, D. | Jackson, M. | Hughes, J. | +6

30

Impact of COVID-19-related disruptions to measles, meningococcal A, and yellow fever vaccination in 10 countries

enthalten in: bioRxiv.org | 2021

von Gaythorpe, K. | Abbas, K. | Huber, J. | +11